Veronesi A, Dal Bo V, Morassut S, Merlo A, Carmignani G, Lo Re G, Carbone A, Magri M D, Talamini R, Francini M
Division of Medical Oncology, Centro di Riferimento Oncologico, Aviano, Italy.
Med Oncol Tumor Pharmacother. 1989;6(2):179-82. doi: 10.1007/BF02985243.
In October 1984, a prospective pilot study aiming to evaluate the feasibility and to preliminarily test the efficacy of the chemotherapy--surgery sequence in locally advanced bladder carcinoma was started at our institutions. Chemotherapy consisted of adriamycin 50 mg mq-2 and cisplatin 50 mg mq-2 on day 1 and fluorouracil 500 mg mq-2 and teniposide 100 mg mq-2 on days 1 and 8; chemotherapy was repeated every 3 weeks for three cycles and followed by surgery (radical cystectomy; TUR if radical surgery medically contraindicated). The characteristics of the 28 patients so far treated include: T3b in 26 patients, local relapse after surgery in two, nodal metastases in seven. Twenty-five patients were male and three female, median age was 61 yr (range 42-75). Clinical response following chemotherapy was: complete remission (CR) in five patients, partial remission (PR) in 15, stable disease (SD) in three, progression (PRO) in two. Three patients are not evaluable. Treatment was moderately well tolerated. Thirteen patients underwent radical surgery, three exploratory surgery, three TUR; refusal in three patients, early death in two, too early in one. No evidence of disease was found in the surgical specimen of five patients (three CR, two PR), microscopic residual disease in four PR patients, gross residual disease in 11 patients (one CR, six PR, two SD, two PRO). Actuarial median survival (all 28 patients) is 45% at 36 months. These preliminary results suggest that the combination of chemotherapy and surgery is feasible and may be effective in these poor prognosis patients.
1984年10月,我们机构开展了一项前瞻性试验性研究,旨在评估化疗-手术序列治疗局部晚期膀胱癌的可行性并初步测试其疗效。化疗方案为第1天给予阿霉素50mg/m²和顺铂50mg/m²,第1天和第8天给予氟尿嘧啶500mg/m²和替尼泊苷100mg/m²;每3周重复化疗3个周期,随后进行手术(根治性膀胱切除术;若有手术医学禁忌证则行经尿道切除术)。截至目前接受治疗的28例患者的特征包括:26例为T3b期,2例术后局部复发,7例有淋巴结转移。25例为男性,3例为女性,中位年龄为61岁(范围42 - 75岁)。化疗后的临床反应为:5例完全缓解(CR),15例部分缓解(PR),3例疾病稳定(SD),2例病情进展(PRO)。3例患者无法评估。治疗耐受性中等。13例患者接受了根治性手术,3例接受了 exploratory手术,3例接受了经尿道切除术;3例患者拒绝治疗,2例早期死亡,1例因时间过早无法评估。5例患者(3例CR,2例PR)的手术标本中未发现疾病证据,4例PR患者有镜下残留病灶,11例患者(1例CR,6例PR,2例SD,2例PRO)有肉眼残留病灶。28例患者的精算中位生存期在36个月时为45%。这些初步结果表明,化疗与手术联合治疗在这些预后较差的患者中是可行的,且可能有效。